Bacillus clausii 088AE

Bacillus clausii 088AE is a spore-forming probiotic strain that produces clausin, a lantibiotic antimicrobial peptide active against Gram-positive pathogens including Listeria monocytogenes. It colonizes the gut transiently, competing with pathogens and supporting intestinal barrier integrity, particularly during and after antibiotic therapy.

Origin & History

Bacillus clausii 088AE (also known as Alkalihalobacillus clausii 088AE) is a spore-forming probiotic strain originally isolated from commercial probiotic formulations and recognized as GRAS under GRN 971. This soil-associated bacterium is produced through fermentation and sporulation processes typical for probiotic bacteria, with no plant source or chemical extraction required.

Historical & Cultural Context

No historical or traditional medicine use is documented for B. clausii 088AE. This is a modern, commercially developed clinical probiotic strain without references to traditional medicine systems.

Health Benefits

• Alleviates antibiotic-associated diarrhea in children, adolescents, and adults (cited in genomic safety studies referencing Maity and Gupta 2021, though specific clinical data not provided)
• Produces clausin antimicrobial peptide that inhibits Gram-positive pathogens including Listeria monocytogenes, Staphylococcus aureus, and Micrococcus luteus (in vitro evidence)
• Demonstrates high acid and bile tolerance enabling gut colonization (genomic evidence)
• Shows gut mucosa adhesion properties supporting probiotic activity (genomic traits identified)
• Contains no virulence genes or transferable antibiotic resistance, supporting safety profile (whole-genome sequencing confirmed)

How It Works

Bacillus clausii 088AE produces clausin, a lantibiotic-class antimicrobial peptide that disrupts cell membrane integrity in Gram-positive pathogens by binding lipid II, a critical peptidoglycan precursor, thereby inhibiting cell wall biosynthesis. The strain's spores survive gastric acid and bile salts, germinating in the small intestine where vegetative cells secrete enzymes including amylases and proteases that modulate luminal pH and compete with pathogenic bacteria for adhesion sites. Additionally, the strain may stimulate secretory IgA production and modulate toll-like receptor signaling to temper intestinal inflammatory responses during dysbiosis.

Scientific Research

Limited clinical trial data is available for B. clausii 088AE specifically, with efficacy for antibiotic-associated diarrhea referenced in genomic studies but without detailed RCT data or PMIDs provided. The strain's safety and probiotic properties are primarily supported by whole-genome sequencing and in vitro studies rather than human clinical trials.

Clinical Summary

Clinical evidence for Bacillus clausii 088AE specifically is limited, with most human data extrapolated from broader Bacillus clausii multi-strain formulations (e.g., Enterogermina) studied in randomized controlled trials across Italy and South Asia. A 2021 genomic and safety characterization study by Maity and Gupta confirmed absence of transmissible virulence and resistance genes in strain 088AE, supporting its safety profile but not providing independent efficacy endpoints. Multi-strain Bacillus clausii trials in children with acute diarrhea (n ranging from 100 to 400 participants) have reported reductions in diarrhea duration of approximately 1 to 1.5 days compared to placebo, though strain-specific attribution to 088AE cannot be isolated from these results. Overall, the evidence base is preliminary and strain-specific randomized trials with quantified clinical outcomes for 088AE alone are lacking.

Nutritional Profile

Bacillus clausii 088AE is a spore-forming, Gram-positive probiotic bacterium, not a conventional food source, so classical macronutrient profiling (fat, carbohydrate, protein per serving) is not the primary framework. Its nutritional and bioactive significance lies in its metabolic outputs and probiotic functionality. Key bioactive compounds and characteristics include: • **Clausin (lantibiotic/antimicrobial peptide):** A ribosomally synthesized post-translationally modified peptide (RiPP) of the lantibiotic class, produced at concentrations sufficient to inhibit Gram-positive pathogens in vitro (exact yield strain-dependent, typically in the low µg/mL range in culture supernatants). Clausin disrupts target cell membranes via lipid II binding. • **Spore-associated components:** Endospores contain dipicolinic acid (DPA, ~5–15% of spore dry weight) chelated with calcium, contributing to extreme acid and bile resistance. This ensures high gastrointestinal survival and effective delivery to the intestinal mucosa — a significant bioavailability advantage over many vegetative-cell probiotics. • **B-vitamins (putative):** Genomic analyses of B. clausii strains commonly reveal biosynthetic gene clusters for riboflavin (B2), folate (B9), and cobalamin (B12) precursors, though quantitative production data specific to strain 088AE are not published. Related B. clausii strains have been reported to synthesize riboflavin in the range of ~0.5–2 mg/L in optimized fermentation conditions. • **Exopolysaccharides (EPS):** B. clausii strains may produce EPS with prebiotic-like and immunomodulatory properties; yields are typically in the range of 50–300 mg/L in culture, though strain 088AE-specific data are limited. • **Short-chain fatty acids (SCFAs):** When metabolically active in the gut, B. clausii contributes to local acetate and minor lactate production, supporting colonocyte nutrition and gut barrier integrity. Quantification is context-dependent (diet, microbiome composition). • **Alkaline proteases and other enzymes:** B. clausii is an alkaliphilic organism producing extracellular proteases and catalase, which may aid protein digestion and reduce oxidative stress in the gut lumen. • **Cell wall components:** Peptidoglycan and lipoteichoic acid serve as microbe-associated molecular patterns (MAMPs) that interact with TLR2 and NOD2 receptors, modulating innate immune responses. • **Protein content of biomass:** Dried B. clausii spore/cell biomass is approximately 50–65% protein by dry weight, though consumed doses (typically 2 × 10⁹ CFU per dose) represent negligible caloric or macronutrient intake (< 0.01 g protein per dose). • **Mineral content:** Spores contain chelated calcium and manganese essential for spore stability; however, the amounts per probiotic dose are nutritionally insignificant. **Bioavailability notes:** The spore form confers exceptional resistance to gastric acid (pH 1.5–3.0), bile salts (up to 0.3–1%), and heat, ensuring near-complete transit survival to the small and large intestine where germination and metabolic activity occur. This represents a superior bioavailability profile for probiotic delivery compared to most Lactobacillus and Bifidobacterium vegetative-cell preparations, which may suffer 1–3 log reductions during gastric transit. The bioactive clausin peptide is produced in situ in the gut post-germination, maximizing local antimicrobial efficacy.

Preparation & Dosage

No clinically studied dosage ranges or standardization details are specified for B. clausii 088AE. The strain is commercially available as spores in probiotic formulations, though quantitative dosing from human trials is absent. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other Bacillus spore probiotics, Lactobacillus strains, Saccharomyces boulardii, Prebiotics (FOS/GOS), Digestive enzymes

Safety & Interactions

Bacillus clausii 088AE is generally regarded as safe based on its genomic characterization showing no transferable antibiotic resistance genes or recognized virulence factors, and multi-strain Bacillus clausii preparations have a long safety record in clinical settings. Reported adverse events in human trials are rare and mild, typically limited to transient bloating or flatulence. Because the strain is inherently resistant to several antibiotics including rifampicin, bacitracin, and chloramphenicol, it can be co-administered with these agents without loss of viability, which is a therapeutic advantage; however, this resistance profile should be reviewed when considering use alongside other antibiotic regimens. Safety data in immunocompromised patients, pregnant women, and neonates is insufficient, and use in these populations should proceed only under medical supervision.